The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase III trial comparing 5-FU plus cisplatin (CF) versus CF plus docetaxel or radiotherapy as neoadjuvant treatment for locally advanced esophageal cancer: 5-year follow-up from JCOG1109.
 
Ken Kato
Honoraria - BMS; Lilly; Ono Pharmaceutical
Consulting or Advisory Role - Bayer; BeiGene; MSD; Oncolys BioPharma; Ono Pharmaceutical
Speakers' Bureau - Bristol-Myers Squibb Japan; MSD; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); Bayer (Inst); Beigene (Inst); Chugai Pharma (Inst); MSD Oncology (Inst); Ono Pharmaceutical (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Yoshinori Ito
No Relationships to Disclose
 
Hiroyuki Daiko
No Relationships to Disclose
 
Soji Ozawa
No Relationships to Disclose
 
Takashi Ogata
Speakers' Bureau - Bristol Myers Squibb Foundation; MSD; Ono Pharmaceutical
 
Hiroki Hara
Honoraria - Bristol-Myers Squibb; Chugai Pharma; Daiichi Sankyo/UCB Japan; Lilly; Merck Serono; Miyarisan pharmaceutical; MSD; Ono Pharmaceutical; Taiho Pharmaceutical; Takeda; Yakult Honsha
Consulting or Advisory Role - Boehringer Ingelheim; Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Ono Pharmaceutical
Research Funding - ALX Oncology (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb Japan (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Janssen Oncology (Inst); Jazz Pharmaceuticals (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Takashi Kojima
Honoraria - AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Covidien; EA Pharma; Japan Esophageal Society; Japanese Society of Pharmaceutical Health Care and Sciences; Kyowa Kirin International; Liang Yi Hui Healthcare; MSD; Ono Pharmaceutical; Taiho Pharmaceutical
Consulting or Advisory Role - Boehringer Ingelheim; CMIC; NPT Co.,Ltd.
Research Funding - Astellas Amgen BioPharama (Inst); AstraZeneca (Inst); BeiGene (Inst); Chugai Pharma (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)
 
Tetsuya Abe
No Relationships to Disclose
 
Takeo Bamba
No Relationships to Disclose
 
Masaya Watanabe
No Relationships to Disclose
 
Hirofumi Kawakubo
No Relationships to Disclose
 
Yuichi Shibuya
No Relationships to Disclose
 
Yasuhiro Tsubosa
No Relationships to Disclose
 
Naoki Takegawa
No Relationships to Disclose
 
Takeshi Kajiwara
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Lilly; Taiho Pharmaceutical
 
Hideo Baba
Honoraria - Ono Pharmaceutical
Research Funding - Asahi Kasei (Inst); AstraZeneca Japan (Inst); bitBiome (Inst); Chugai Pharma (Inst); Shin Nippon Biomedical (Inst); Taiho Pharmaceutical (Inst)
 
Masaki Ueno
No Relationships to Disclose
 
Ryunosuke Machida
No Relationships to Disclose
 
Kenichi Nakamura
Honoraria - AstraZeneca; Chugai Pharma; Lilly; Taiho Pharmaceutical; Takeda
Research Funding - Astellas Pharma (Inst); Boehringer Ingelheim Seiyaku (Inst); Bristol-Myers Squibb Japan (Inst); Chugai/Roche (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Merck (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Otsuka (Inst); Pfizer (Inst); SERVIER (Inst); SymBio Pharmaceuticals (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst)
 
Yuko Kitagawa
Honoraria - Asahi Kasei; ASKA Pharmaceutical Co., Ltd.; AstraZeneca Japan; Bristol-Myers Squibb K.K.; Chugai Foundation for Innovative Drug Discovery Science; Chugai Pharma; DAIICHI SANKYO COMPANY, LIMITED; EA Pharma; Ethicon; Intuitive Surgical; Kaken Pharmaceutical; Miyarisan pharmaceutical; MSD K.K.; Nippon Covidien; Nippon Kayaku; Olympus; Ono Pharmaceutical; Otsuka; Shionogi; Smith & Nephew; Sysmex; Taiho Pharmaceutical; Toray Industries
Consulting or Advisory Role - Bristol-Myers Squibb K.K.; Ono Pharmaceutical
Research Funding - Asahi Kasei (Inst); Chugai Pharma (Inst); Eisai (Inst); Kaken Pharmaceutical (Inst); Kowa (Inst); Kyouwa Hakkou Kirin Co., Ltd. (Inst); Nippon Covidien (Inst); Otsuka (Inst); Otsuka (Inst); Sumitomo Pharma Co., Ltd. (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Teijin Pharma (Inst); TSUMURA & CO. (Inst)